GOLDEN, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced the commercial availability of specialized products to support stem cell research and drug development. This new product line called, “Tools for Stem Cell and Drug Development™” features novel products to support research involving mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPS) and cancer research that specifically utilizes stem cells that preferentially migrate to cancer cells and facilitate their destruction. Vitro Diagnostic’s newly revised website, www.vitrobiopharma.com, details our new products. The current total market for stem cell research tools is estimated to be about $900 million and is projected to expand at 10 to 20% per year in the near future.
